This inventor holds 12 USPTO granted patents and 11 published patent applications and 5 EPO patents. Top assignees: Isarna Therapeutics Gmbh, Secarna Pharmaceuticals Gmbh & Co Kg, Antisense Pharma Gmbh. Active years: 2012-2024.
Location History:
- Obertraubling, DE (2012 - 2018)
- Puchheim, DE (2018 - 2024)
Company Filing History:
5 out of 6 
3 out of 3 
2 out of 10 Years Active: 2012-2024
Title: The Innovations of Frank Jaschinski: A Pioneer in Medical Research
Introduction
Frank Jaschinski, a distinguished inventor based in Obertraubling, Germany, has made significant contributions to the field of medical research with a total of nine patents to his name. His work focuses on innovative approaches to treating inflammatory disorders and cancer through targeted oligonucleotide therapies.
Latest Patents
Among his latest innovations, Jaschinski has developed a novel approach for treating inflammatory disorders, which targets ROR gamma t mRNA. This invention includes oligonucleotides composed of 10 to 22 modified or unmodified nucleotides that are complementary to selected regions of RORC, specifically transcript variant 2 mRNA (RORC2), which encodes for the ROR gamma t protein. Another key invention is the Modified TGF-beta oligonucleotides, which consist of 10 to 20 nucleotides from selected regions of the TGF-beta1, TGF-beta2, or TGF-beta3 nucleic acid sequences. These oligonucleotides include modified nucleotides such as LNA (locked nucleic acid), ENA (enhanced nucleic acid), and others. These patents aim to address various medical conditions including malignancies, immunologic diseases, and fibrosis.
Career Highlights
Jaschinski has been associated with notable companies in the pharmaceutical field, such as Isarna Therapeutics GmbH and Antisense Pharma GmbH. His work in these organizations has positioned him as a key contributor to the advancement of therapeutic approaches in the treatment of various diseases.
Collaborations
Throughout his career, Frank Jaschinski has collaborated with esteemed colleagues such as Michel Janicot and Eugen Uhlmann. These partnerships have allowed for a cross-pollination of ideas and strategies, ultimately leading to innovations that could significantly improve patient outcomes in medical care.
Conclusion
Frank Jaschinski stands out as a prolific inventor in the realm of medical research. With nine patents, his work on innovative treatments using oligonucleotide technologies highlights his commitment to advancing healthcare solutions. As the field of medicine continues to evolve, Jaschinski's contributions are likely to play a crucial role in shaping future therapeutic practices.